Huaiqihuang Granules in the Treatment of Children with Bronchial Asthma Real World Study Officially Launched

On November 7, 2015, the real-world research on the treatment of bronchial asthma in children with Huaiqihuang Granules was held at Shangri-La Hotel, Nanchang. It is jointly organized by the main research unit Beijing Capital Institute of Pediatrics, the bidding unit Qidong Gaitianli Pharmaceutical Co., Ltd., the contract research organization Beijing Qihuang Drug Clinical Research Center and the data management and statistics unit Haiborui (Beijing) Data Technology Co., Ltd., a total of 22 clinical research units across the country participated in the meeting.

Professor Chen Yuzhi of Capital Institute of Pediatrics, a well-known asthma expert in China, presided over and introduced the general situation and research background of Huaiqihuang granule research project. At present, the treatment of asthma in children is mainly long-term inhaled hormones or oral anti-leukotriene drugs. Although it has a certain effect, it has certain limitations. The former has a small impact on the height of children and parents have concerns about inhaled hormones, which affects patients' medication compliance. The latter has high medical costs, weak efficacy, and some patients are ineffective. Foreign research results show that immunomodulators can reduce the onset of wheezing in preschool children. As an immunomodulator that has been used in clinical practice for many years, Huaiqihuang Granules has been recognized by experts and patients for its effectiveness and safety in the intervention of recurrent respiratory tract infections, and has a preliminary effect on the control of asthma, but it needs the support of clinical data.

Lu Zhengxin, deputy general manager of Qidong Gaitianli Pharmaceutical Co., Ltd., introduced the efficacy characteristics and the latest research progress of Huaiqihuang granules, hoping to apply the latest research to the clinical trials of bronchial asthma in children, so as to better prevent and treat asthma in children.

Professor Liu Chuanhe of Capital Institute of Pediatrics introduced the clinical research program and research process of Huaiqihuang Granules, arranged the research progress in detail, and looked forward to the expected results. Tian Yiqun, the director of Beijing Qihuang Drug Clinical Research Center, introduced the origin and research status of real world research (RWS), and compared the advantages and disadvantages of real world research (RWS) and randomized controlled trial (RCT). The biggest advantage of RWS is that it can provide better evidence for the effectiveness and safety of drugs in real clinical environment, and the evidence obtained is more direct, true, objective and comprehensive, in line with the research model from the clinic to the clinic, the clinical data and the results of the analysis are more recognized.

Beijing Qihuang Drug Clinical Research Center is a professional CRO company with the earliest establishment in China and rich research on traditional Chinese medicine and ethnic medicine. They will provide excellent professional management team and efficient and stable monitoring team to manage and quality control the research project to ensure the high-quality completion of the research.

We wish the clinical study a smooth and successful outcome.